A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)

Inclusion Criteria:

• At the time of screening, has stage 4 or 5 chronic kidney disease (Parts 1 and 2) orend-state kidney disease on peritoneal dialysis (Part 3).

• Has a body mass index (BMI) ≥ 18 and ≤ 45 kg/m^2.

Exclusion Criteria:

• Has a history of cancer, including adenocarcinoma, except adequately treatednon-melanomatous skin carcinoma or carcinoma in situ of the cervix or othermalignances which have been successfully treated ≥ 5 years prior to prestudy withappropriate follow-up.

• Has a history of deep vein thrombosis or pulmonary embolism, a history of vascularaccess thrombosis within 1 month prior to enrollment, or has a personal or familyhistory of bleeding disorder.

• Has a history of gastrointestinal (GI) bleeding, duodenal polyps, or gastric ulcerin the last 5 years or severe hemorrhoidal bleed in the last 3 months.

• Has a history of or current frequent epistaxis within the last 3 months or activegingivitis.

• Has ongoing anticoagulant therapy or antiplatelet therapy. Aspirin is permitted.

• Has planned significant dental procedures at the time of screening or pre-dose orother planned surgical procedures within duration of participation of study.

• Is positive for hepatitis B surface antigen or human immunodeficiency virus (HIV).

• Has had major surgery and/or donated or lost 1 unit of blood (approximately 500 mL)within 4 weeks prior to the pre-study visit.

• Has a history (participant recall) of receiving any human immunoglobulin preparationsuch as intravenous immunoglobulin (IVIG) or RhoGAM within the last year.

• Has a history (participant recall) of receiving any biological therapy (includinghuman blood products or monoclonal antibodies; excluding erythropoietin and insulin)within the last 3 months or vaccination within the last 1 month, except the seasonalflu and pneumococcal vaccine or COVID-19 vaccine.